Aaron Cowen’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$147M Sell
4,776,423
-254,570
-5% -$6.29M 2.69% 10
2026
Q1
$109M Sell
5,030,993
-157,865
-3% -$3.41M 2.78% 10
2025
Q4
$124M Buy
5,188,858
+1,500,000
+41% +$30.6M 2.53% 7
2025
Q3
$50.2M Hold
3,688,858
1.28% 30
2025
Q2
$30M Buy
3,688,858
+1,127,954
+44% +$9.63M 0.91% 35
2025
Q1
$20.1M Buy
2,560,904
+1,984,748
+344% +$23M 0.75% 37
2024
Q4
$8.58M Sell
576,156
-87,447
-13% -$1.43M 0.29% 57
2024
Q3
$10.1M Sell
663,603
-293,701
-31% -$4.63M 0.32% 52
2024
Q2
$14.6M Hold
957,304
0.54% 45
2024
Q1
$18.1M Hold
957,304
0.67% 42
2023
Q4
$18.3M Buy
957,304
+360,205
+60% +$5.76M 0.83% 38
2023
Q3
$10.7M Buy
+597,099
New +$12M 0.58% 44

Other funds holding RCUS

Aaron Cowen's RCUS Position: Q2 2026 in Review

Aaron Cowen reduced its Arcus Biosciences (RCUS) stake by 5.1% in Q2 2026, selling an estimated $6.29M and leaving 4,776,423 shares worth $147M. The position accounts for 2.69% of the portfolio, ranked #10.

Aaron Cowen first reported a position in RCUS in Q3 2023 and has held it in 12 quarters since. 228 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Aaron Cowen held 4,776,423 shares of Arcus Biosciences worth $147M as of Q2 2026.
  • Aaron Cowen sold 254,570 Arcus Biosciences shares in Q2 2026, an estimated $6.29M.
  • Arcus Biosciences made up 2.69% of Aaron Cowen's portfolio in Q2 2026, its #10 holding.
  • Aaron Cowen first reported a position in Arcus Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 228 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.